Monon Bioventures Receives Nearly $400,000 To Develop Purdue-Discovered Glioblastoma Treatment
September 23, 2022
September 23, 2022
WEST LAFAYETTE, Indiana, Sept. 23 (TNSres) -- Purdue University issued the following news release:
* * *
Monon Bioventures, Genezen and Purdue University pharmacy researcher form partnership to 'arm' natural killer cells and prove manufacturability
* * *
"Glioblastoma is one of the most aggressive cancers of the central nervous system. It grows, multiplies and spreads quickly, is almost always lethal, and there is no effective cure. New, e . . .
* * *
Monon Bioventures, Genezen and Purdue University pharmacy researcher form partnership to 'arm' natural killer cells and prove manufacturability
* * *
"Glioblastoma is one of the most aggressive cancers of the central nervous system. It grows, multiplies and spreads quickly, is almost always lethal, and there is no effective cure. New, e . . .